Subscribe

Ebos Group Limited (EBO.NZ)

NZD22.58 +0.21 (+0.94%)
NZ NZE Healthcare Medical - Distribution
Address 737 Bourke Street 3008
Docklands, VIC, NZ
CEO Adam Luke Hall
Website ebosgroup.com
IPO 2000-01-04
ISIN NZEBOE0001S6

Explore sections of this company profile

Also trades on Australian Securities Exchange · EBO.AX (AUD) New Zealand Exchange · EBO.NZ (NZD) Other OTC · EBOSY (USD)
Description

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. Further, it offers healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition, treats, clean-up, and grooming products and accessories; and wholesales veterinary products. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
NZD22.58 +0.21 (+0.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
248.8K
Beta
0.16
Float Shares
195.00M
Free Float %
95.1%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.89% -0.92% +1.13% -5.17% -25.43% -25.67% -44.74% -44.51% -37.58% +25.95% +22,736.23%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
22.58
DCF (Unlevered) 47.85 +111.9%
DCF (Levered) 40.64 +80.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 88% Bullish
Rating 2026-06 Change
Strong Buy 1 0
Buy 6 0
Hold 0 0
Sell 0 0
Strong Sell 1 0
Quality scores
Altman Z-Score
4.16
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Distribution: +5.6%
    -8.3% Q4'25: +7.4% (vs Q4'23)
  • ✗
    EPS growth Medical - Distribution: +4.9%
    -23.5% Q4'25: -12.8% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Distribution: +37.6%
    +3.3% ★ Q4'25: -0.2% (vs Q4'23)
  • ✗
    EBIT margin Medical - Distribution: +3.0%
    +3.2% ★ Q4'25: +2.8% (vs Q4'23)
  • ✗
    ROIC Medical - Distribution: +5.7%
    +6.7% ★ Q4'25: +11.9% (vs Q4'23)
  • ✗
    Share dilution Medical - Distribution: +0.0%
    +2.7% Q4'25: +7.2% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×
    3.01× Q4'25: 2.16× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.16) × ERP
WACC = 71% × Ke + 29% × Kd (7.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 47.85 Current price: 22.58
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Jun 2015
actual 		Jun 2016
actual 		Jun 2017
actual 		Jun 2018
actual 		Jun 2019
actual 		Jun 2020
actual 		Jun 2021
actual 		Jun 2022
actual 		Jun 2023
actual 		Jun 2024
actual 		Jun 2025
actual 		Jun 2026
10 Rev. Ana.
6 EPS Ana. 		Jun 2027
10 Rev. Ana.
6 EPS Ana. 		Jun 2028
9 Rev. Ana.
4 EPS Ana. 		Jun 2029
4 Rev. Ana.
1 EPS Ana. 		Jun 2030
5 Rev. Ana.
1 EPS Ana.
Revenue
6.07B
est: 6.07B (-0.1%)
7.10B
est: 6.63B (+7.1%)
7.63B
est: 7.68B (-0.7%)
7.61B
est: 7.73B (-1.5%)
7.25B
est: 7.29B (-0.6%)
9.38B
est: 9.36B (+0.3%)
9.89B
est: 9.82B (+0.6%)
11.45B
est: 11.45B (+0.1%)
13.32B
est: 13.22B (+0.7%)
14.41B
est: 14.44B (-0.2%)
13.21B
est: 13.14B (+0.5%)
16.47B
15.92B – 16.71B
+25.3% YoY
17.12B
16.52B – 17.53B
+4.0% YoY
17.79B
17.17B – 18.13B
+3.9% YoY
18.95B
18.29B – 19.31B
+6.5% YoY
20.05B
19.36B – 20.43B
+5.8% YoY
EBITDA
198.99M
est: 259.38M (-23.3%)
227.98M
est: 283.07M (-19.5%)
236.51M
est: 327.89M (-27.9%)
274.16M
est: 329.98M (-16.9%)
264.65M
est: 311.46M (-15.0%)
349.59M
est: 399.47M (-12.5%)
383.52M
est: 419.50M (-8.6%)
440.15M
est: 488.73M (-9.9%)
630.86M
est: 564.64M (+11.7%)
648.56M
est: 754.28M (-14.0%)
579.91M
est: 686.73M (-15.6%)
860.50M
831.58M – 872.81M
+25.3% YoY
894.73M
862.92M – 915.75M
+4.0% YoY
929.48M
897.32M – 947.13M
+3.9% YoY
990.06M
955.81M – 1.01B
+6.5% YoY
1.05B
1.01B – 1.07B
+5.8% YoY
EBIT
174.88M
est: 201.79M (-13.3%)
203.29M
est: 220.22M (-7.7%)
210.67M
est: 255.09M (-17.4%)
239.43M
est: 256.71M (-6.7%)
230.46M
est: 242.31M (-4.9%)
271.56M
est: 310.77M (-12.6%)
304.78M
est: 326.36M (-6.6%)
352.81M
est: 380.22M (-7.2%)
480.18M
est: 439.28M (+9.3%)
509.61M
est: 508.53M (+0.2%)
421.73M
est: 462.99M (-8.9%)
580.15M
560.65M – 588.44M
+25.3% YoY
603.22M
581.78M – 617.39M
+4.0% YoY
626.65M
604.97M – 638.55M
+3.9% YoY
667.50M
644.40M – 680.18M
+6.5% YoY
706.32M
681.88M – 719.74M
+5.8% YoY
Net Income
105.94M
est: 135.13M (-21.6%)
127.00M
est: 163.59M (-22.4%)
132.85M
est: 178.19M (-25.4%)
149.56M
est: 194.35M (-23.0%)
144.07M
est: 188.73M (-23.7%)
173.95M
est: 212.79M (-18.3%)
199.09M
est: 241.56M (-17.6%)
216.15M
est: 278.51M (-22.4%)
275.74M
est: 308.39M (-10.6%)
296.71M
est: 333.33M (-11.0%)
231.66M
est: 292.05M (-20.7%)
290.53M
283.96M – 297.10M
-0.5% YoY
292.87M
267.16M – 318.59M
+0.8% YoY
331.90M
311.27M – 352.52M
+13.3% YoY
328.90M
314.10M – 337.02M
-0.9% YoY
—
— – —
-100.0% YoY
SGA
237.26M
est: 259.71M (-8.6%)
263.95M
est: 283.43M (-6.9%)
295.59M
est: 328.30M (-10.0%)
357.37M
est: 330.39M (+8.2%)
357.61M
est: 311.85M (+14.7%)
347.69M
est: 399.97M (-13.1%)
382.43M
est: 420.03M (-9.0%)
467.06M
est: 489.34M (-4.6%)
578.28M
est: 565.35M (+2.3%)
619.43M
est: 617.21M (+0.4%)
632.72M
est: 561.94M (+12.6%)
704.13M
680.46M – 714.20M
+25.3% YoY
732.14M
706.11M – 749.34M
+4.0% YoY
760.57M
734.26M – 775.02M
+3.9% YoY
810.15M
782.12M – 825.54M
+6.5% YoY
857.27M
827.61M – 873.56M
+5.8% YoY
EPS
0.71
est: 0.68 (+3.7%)
0.84
est: 0.83 (+1.3%)
0.88
est: 0.90 (-2.5%)
0.98
est: 0.98 (-0.5%)
0.94
est: 0.96 (-1.7%)
1.06
est: 1.08 (-1.7%)
1.22
est: 1.22 (-0.3%)
1.22
est: 1.41 (-13.5%)
1.45
est: 1.56 (-6.9%)
1.53
est: 1.73 (-11.5%)
1.18
est: 1.50 (-21.6%)
1.47
1.44 – 1.51
-2.0% YoY
1.47
1.35 – 1.61
-0.1% YoY
1.66
1.58 – 1.79
+12.7% YoY
1.67
1.59 – 1.71
+0.5% YoY
—
— – —
-100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-06-12 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-06-11 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-06-10 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-06-09 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-06-08 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-06-05 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-06-04 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-06-03 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-06-02 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-29 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-28 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-27 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-26 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-25 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-22 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-21 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-20 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-19 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-18 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-15 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-14 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-13 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-12 B+ 3/5 5/5 4/5 4/5 1/5 2/5 3/5
2026-05-11 B+ 3/5 5/5 3/5 4/5 1/5 2/5 3/5
2026-05-08 B+ 3/5 5/5 3/5 4/5 1/5 2/5 3/5
2026-05-07 B+ 3/5 5/5 3/5 4/5 1/5 2/5 3/5
2026-05-06 B+ 3/5 5/5 3/5 4/5 1/5 2/5 3/5
2026-05-05 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-05-04 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-05-01 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-30 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-29 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-28 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-24 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-23 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-22 B+ 3/5 5/5 3/5 4/5 1/5 3/5 3/5
2026-04-21 A- 4/5 5/5 3/5 5/5 1/5 3/5 3/5
2026-04-20 A- 4/5 5/5 3/5 5/5 1/5 3/5 3/5
2026-04-17 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5
2026-04-16 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5
2026-04-15 B+ 3/5 5/5 3/5 5/5 1/5 2/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
669.47M
OE per share TTM
3.43
Owner's Yield
15.31%
Maintenance CapEx ratio
28.95%
Maint CapEx / Avg PPE
5.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
76.2K
Shares Outstanding
205.04M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Adam Luke Hall BCOMM Chief Executive Officer 5M male
Alistair Gray Chief Financial Officer — male
Brett Barons Chief Executive Officer of Symbion & Healthcare Distribution — male
Grant Viney Chief Executive Officer of EBOS Animal Care — male
Jacinta McCarthy Executive General Manager of Human Resources — female
Janelle Cain General Counsel — female
Kristine James Chief Executive Officer of Medical Technology — female
Leonard Hansen Chief Accountant & Chief Risk Officer — male
Martin Krauskopf Chief Strategy & Corporate Development Officer — male
Mithran Naiker Chief Information Officer — male
Simon Bunde Executive General Manager of Strategic Operations, ESG & Innovation — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Distribution